Table 2 COPE: event rates and point estimates of outcomes by cancer type

From: CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer

 

Heme

Solid

Death within 30 d of discharge

 Event rate (%)

12 (54.6%)

26 (33.3%)

 Unadjusted OR (95% CI)

2.4 (0.82–7.06)

ref

 Adjusted OR (95% CI)a

3.3 (1.01–10.8)

ref

 Adjusted HR (95% CI)a

2.6 (1.19–5.54)

ref

  1. aLogistic regression-computed OR and Cox regression-computed HR, respectively. Adjusted for age, gender, smoking status, active cancer status and ECOG performance status.
  2. ref, reference population.
Back to article page